MEI Pharma To Host Annual Meeting Of Stockholders

              MEI Pharma To Host Annual Meeting Of Stockholders

Live Webcast from San Francisco on Tuesday, March 26

PR Newswire

SAN DIEGO, March 20, 2013

SAN DIEGO, March 20, 2013 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Pacific
time on Tuesday, March 26, 2013 at the offices of Morgan, Lewis & Bockius LLP,
located at One Market, Spear Street Tower in San Francisco, to consider and
vote on certain matters, including the election of a director, the
ratification of the appointment of the Company's independent registered public
accounting firm, the approval of the amendment and restatement of the
Company's certificate of incorporation, and the approval of the amendment and
restatement of the Company's equity compensation plan. A live webcast of the
meeting will be accessible at www.meipharma.com/investor. A replay will be
available approximately one hour after the presentation.

(Logo:http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral histone
deacetylase (HDAC) inhibitor being developed for advanced hematologic
malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML). Results from a pilot Phase II clinical trial of Pracinostat in
combination with azacitidine in patients with advanced MDS were presented at
the American Society of Hematology Annual Meeting in December 2012 showing an
overall response rate (CR+CRi+PR) of 89% (eight out of nine). The Company
plans to initiate a randomized, placebo-controlled Phase II trial of
Pracinostat in combination with azacitidine in patients with MDS in June 2013.
In addition, MEI Pharma is developing two drug candidates derived from its
isoflavone-based technology platform, ME-143 and ME-344. For more information,
go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.meipharma.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, +1-858-792-3729, pdespain@meipharma.com
 
Press spacebar to pause and continue. Press esc to stop.